RxDoctor Payments Data

Ravi Bhasker, MD

Family Medicine · Socorro, NMNPI 1326146259

Payments from drug & device makers

$337in general payments, 2019–2025

Across 20 payments — averaging $16.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$109
  • Novartis$93
  • Pfizer$49
  • Novo Nordisk$16
  • Phathom Pharmaceuticals, Inc.$16
  • Amgen$16
  • plus $38 from 3 others

What the payments were for

  • Food & beverage$32195%
  • Education$165%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$337 in reported general payments places this provider in the 65th percentile of 717 family medicine providers in New Mexico.

See all family medicine providers in New Mexico

Medicare billing

Part B allowed, 2024
$213,484
Medicare patients
259
Services billed
4,451

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide215$216,401
EliquisApixaban44$37,702
TrulicityDulaglutide36$37,085
XifaxanRifaximin11$20,981
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen666$13,844
JanuviaSitagliptin Phosphate15$12,467
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog28$8,977
MyrbetriqMirabegron18$8,157
SymbicortBudesonide/Formoterol Fumarate26$7,609
Novolog FlexpenInsulin Aspart59$7,068
Tresiba Flextouch U-100Insulin Degludec14$6,781
Lantus SolostarInsulin Glargine,hum.Rec.Anlog59$6,676
Atorvastatin Calcium363$6,399
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen372$6,273
Rezvoglar KwikpenInsulin Glargine-Aglr55$5,309

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$16$216,401215 claims
PfizerEliquis$49$37,70244 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$109$20,98111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 717 family medicine providers in New Mexico.

Other family medicine in Socorro

See the full list for New Mexico

Where these figures come from

Is this you, or does something look wrong? →